Atricure Stock Performance
| ATRC Stock | USD 23.37 0.20 0.86% |
The firm shows a Beta (market volatility) of 2.15, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, AtriCure will likely underperform. AtriCure has an expected return of -0.57%. Please make sure to confirm AtriCure potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if AtriCure performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AtriCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.86 | Five Day Return 1.26 | Year To Date Return (33.83) | Ten Year Return 48.29 | All Time Return 65.98 |
1 | AtriCure Non-GAAP EPS of -0.21 beats by 0.02, revenue of 106.5M beats by 2.34M | 02/15/2024 |
2 | Disposition of 10000 shares by Robert White of AtriCure at 15.96 subject to Rule 16b-3 | 02/23/2024 |
3 | AtriCure Fell on Competitor Action | 02/28/2024 |
4 | Disposition of 7354 shares by Salvatore Privitera of AtriCure at 36.28 subject to Rule 16b-3 | 03/01/2024 |
5 | Disposition of 8231 shares by Dahlquist Karl S. of AtriCure at 37.36 subject to Rule 16b-3 | 03/05/2024 |
6 | Disposition of 1885 shares by Dahlquist Karl S. of AtriCure at 32.16 subject to Rule 16b-3 | 03/18/2024 |
7 | AtriCures chief legal officer sells shares worth over 60k | 03/20/2024 |
8 | AtriCure Declined due to Concerns Over Anti-Obesity Drug | 03/22/2024 |
9 | Tricares Announces the Appointment of Ahmed Elmouelhi as President Chief Executive Officer | 03/25/2024 |
10 | Disposition of 1500 shares by Justin Noznesky of AtriCure at 30. subject to Rule 16b-3 | 04/01/2024 |
11 | AtriCure exec sells 45.6k in company stock | 04/03/2024 |
12 | AtriCures Buy Rating Reaffirmed at Needham Company LLC - Defense World | 04/11/2024 |
13 | Short Interest in AtriCure, Inc. Rises By 9.4 percent - Defense World | 04/17/2024 |
14 | AtriCure Announces Launch of the cryoSPHERE Probe for Post-Operative Pain Management | 04/18/2024 |
15 | Oppenheimer upgrades AtriCure stock on improved risk-reward | 04/23/2024 |
| Begin Period Cash Flow | 58.1 M |
AtriCure |
AtriCure Relative Risk vs. Return Landscape
If you would invest 3,406 in AtriCure on January 31, 2024 and sell it today you would lose (1,069) from holding AtriCure or give up 31.39% of portfolio value over 90 days. AtriCure is currently does not generate positive expected returns and assumes 2.7635% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than AtriCure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AtriCure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AtriCure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AtriCure, and traders can use it to determine the average amount a AtriCure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2055
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATRC |
Estimated Market Risk
| 2.76 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.57 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AtriCure is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AtriCure by adding AtriCure to a well-diversified portfolio.
AtriCure Fundamentals Growth
AtriCure Stock prices reflect investors' perceptions of the future prospects and financial health of AtriCure, and AtriCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AtriCure Stock performance.
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0324 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 1.05 B | ||||
| Shares Outstanding | 48.37 M | ||||
| Price To Earning | 33.47 X | ||||
| Price To Book | 2.50 X | ||||
| Price To Sales | 2.92 X | ||||
| Revenue | 399.25 M | ||||
| Gross Profit | 245.94 M | ||||
| EBITDA | (16.28 M) | ||||
| Net Income | (30.44 M) | ||||
| Cash And Equivalents | 118.45 M | ||||
| Cash Per Share | 2.55 X | ||||
| Total Debt | 74.49 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | 9.81 X | ||||
| Cash Flow From Operations | 4.42 M | ||||
| Earnings Per Share | (0.66) X | ||||
| Market Capitalization | 1.13 B | ||||
| Total Asset | 613.93 M | ||||
| Retained Earnings | (357.06 M) | ||||
| Working Capital | 191.68 M | ||||
| Current Asset | 74.75 M | ||||
| Current Liabilities | 31.59 M | ||||
About AtriCure Performance
To evaluate AtriCure Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when AtriCure generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare AtriCure Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand AtriCure market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents AtriCure's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 243.38 | 130.21 | |
| Return On Tangible Assets | (0.1) | (0.10) | |
| Return On Capital Employed | (0.06) | (0.06) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.07) | (0.07) |
Things to note about AtriCure performance evaluation
Checking the ongoing alerts about AtriCure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AtriCure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AtriCure generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 399.25 M. Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 245.94 M. | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Oppenheimer upgrades AtriCure stock on improved risk-reward |
- Analyzing AtriCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AtriCure's stock is overvalued or undervalued compared to its peers.
- Examining AtriCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AtriCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AtriCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AtriCure's stock. These opinions can provide insight into AtriCure's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for AtriCure Stock analysis
When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is AtriCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.66) | Revenue Per Share 8.621 | Quarterly Revenue Growth 0.21 | Return On Assets (0.03) | Return On Equity (0.07) |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.